A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
The study is to evaluate the therapeutic effect of metformin as a maintenance therapy in high risk patients with complete remission of diffuse large B lymphoma / stage III follicular lymphoma after chemotherapy in the initial R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus the monoclonal antibody rituximab) regimen
Lymphoma, Large B-Cell, Diffuse|Stage III Follicular Lymphoma
DRUG: Metformin|DRUG: Placebos
Overall Survival, From date of randomization until the date of trail closed or date of death from any cause, whichever came first, up to 100 months
Progress Free Survival, From date of randomization until the date of trail closed or disease progressed, whichever came first, up to 100 months
The study is to evaluate the therapeutic effect of metformin as a maintenance therapy in high risk patients with complete remission of diffuse large B lymphoma / stage III follicular lymphoma after chemotherapy in the initial R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus the monoclonal antibody rituximab) regimen